Developing Story
Linezolid – Antibiotic Repurposing for JAK2V617F Myeloproliferative Neoplasm
A preprint reports that linezolid, an FDA-approved antibiotic, may selectively inhibit JAK2V617F-harboring cells in polycythemia vera across multiple model systems. If confirmed, its existing regulatory status could accelerate repurposing timelines. The finding is pending peer review and clinical validation.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
## Linezolid – Antibiotic Repurposing for JAK2V617F Myeloproliferative Neoplasm
### Overview
Researchers have reportedly discovered that linezolid (LZD), an FDA-approved antibiotic, may ameliorate the phenotype of polycythemia vera (PV) — a myeloproliferative neoplasm — by selectively inhibiting cells harboring the JAK2V617F (JAK2VF) driver mutation (biorxiv, 2026.05.31.729063v1). The finding is described as a potential breakthrough given current treatments' inability to eliminate mutant stem/progenitor cells.
### Background
- **JAK2V617F mutation**: Present in approximately 95% of PV patients; drives excessive hematopoiesis.
- **Current treatment limitations**: Existing therapies suppress symptoms but cannot selectively deplete JAK2VF-harboring cells and are subject to drug resistance.
- **Linezolid**: An oxazolidinone-class antibiotic approved for bacterial infections including MRSA; inhibits mitochondrial protein synthesis.
### Key Findings (Preprint)
- LZD reportedly suppressed cell proliferation and STAT5 signaling in JAK2VF-harboring human erythroleukemia cells.
- The compound altered the cell cycle and increased apoptosis specifically in JAK2VF cells across multiple model systems.
- Results were described as demonstrating selectivity for the mutant over wild-type cells, though peer review is pending.
### Strategic Relevance
- **Drug repurposing opportunity**: If confirmed, LZD's existing FDA approval may substantially reduce development timelines for a PV indication.
- **IP considerations**: Method-of-use patents on repurposed drugs are an active litigation area; first-mover filing around the JAK2VF-LZD mechanism may be commercially significant.
- **Competitive landscape**: Ruxolitinib (Jakafi) dominates the JAK inhibitor space for myeloproliferative neoplasms; a mechanism-differentiated therapy targeting mutant stem cells could command distinct market positioning.
- **Resistance risk**: Linezolid's mitochondrial mechanism is distinct from current JAK inhibitors, potentially offering a non-cross-resistant option.
### Status
Preprint only; peer review pending. Multiple model systems were tested, but clinical validation has not yet been reported.